Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$269.5MCash on Hand
20.6mo Cash Runway
Follow RCKT by emailGet an email when RCKT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about RCKT, unsubscribe in one click. Privacy
📣 What RCKT Says Is Next
mid-2027 · “Prevalence estimates may include undiagnosed or asymptomatic individuals and do not indicate treatment eligibility. o Rocket expects to complete pivotal trial dosing by mid-2027, with topline results anticipated in mid-2028.”
Company press release, Nov 12, 2026 · SEC filing
in 2026 · “Phase 1 Trial Initiation Anticipated in 2026 for RP-A701 in BAG3-Associated Dilated Cardiomyopathy (BAG3-DCM) o Patient screening and enrollment has begun, with initial patient dosing anticipated in the second half of 2026. o The multicenter, dose-escalation study is designed to evaluate the safety, biological activity and preliminary efficacy of RP-A701 in adults with BAG3-DCM.”
Company press release, Aug 10, 2026 · SEC filing
second half of 2026 · “Continued FDA Engagement and Phase 1 Enrollment for RP-A601 in PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) o Rocket continues to engage with the FDA regarding alignment on the design of a potential pivotal study of RP-A601 in PKP2-ACM with regulatory update expected in the second half of 2026.”
Company press release, Aug 10, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 12, 2026 ·
Earnings Reported Q3 2026 net loss of $49.2 million ($0.43 per share) with cash, equivalents and investments of $279.4 million, expected to fund operations into Q3 2028. FDA alignment set the path to complete the RP-A501 Danon pivotal trial by mid-2027. Form 8-K · SEC filing · Press release
Oct 6, 2026 ·
Financing Rocket entered a Hercules Capital loan agreement of up to $150.0 million. $35.0 million was funded at closing on September 30, 2026, with further tranches of $20.0 million, $15.0 million, $30.0 million and up to $50.0 million, the last subject to Hercules investment committee approval. Maturity is October 1, 2030. Form 8-K · SEC filing · Press release
Sep 15, 2026 ·
Regulatory FDA aligned with Rocket on continuing enrollment and dosing in the pivotal Phase 2 RP-A501 Danon disease trial at a recalibrated dose of 3.8 × 10¹³ GC/kg. Form 8-K · SEC filing · Press release
Aug 27, 2026 ·
Leadership Adopted a severance and change in control program on Aug 21, 2026, with benefits scaled by role, and entered new or amended executive employment agreements with the CEO, General Counsel and COO. Form 8-K · SEC filing
Aug 10, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Aug 10, 2026 ·
Earnings Rocket reported Q2 2026 net income of $123.2 million, or $1.08 diluted per share, driven by a $178.8 million other-income gain from the $180 million Priority Review Voucher sale. Cash and investments were $283.7 million, with runway into Q2 2028. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jun 2028 · Phase 2 · Recruiting · A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease Registry primary completion date, not a results date
Sep 2028 · Phase 1 · Recruiting · A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM) Registry primary completion date, not a results date
Jun 2029 · Phase 1 · Recruiting · A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy Registry primary completion date, not a results date
Dec 2029 · N/A · Recruiting · Danon Disease Natural History Study Registry primary completion date, not a results date
Dec 2030 · N/A · Recruiting · PKP2-ACM Natural History Study Registry primary completion date, not a results date
May 2026 · Phase 2 · Active Trial · Gene Therapy for Fanconi Anemia, Complementation Group A Registry date passed, readout not confirmed
Also used in these trials (approved or third-party drugs, not RCKT's own candidates): Filgrastim, Plerixafor, Prednisone.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
RCKT holds $269.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $39.3M/quarter from operations,
an estimated runway of 20.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:13 · Low
Cash runway 21 months +8
ATM program on file since Mar 2026 +15
Shelf registration (S-3, Mar 2026) +10
Company says cash lasts into the third quarter of 2028 -10Based on the Company's current operating plan and its cash, cash equivalents, investments, including proceeds received from the PRV sale and the initial borrowing from the Loan Agreement, the Company believes it has sufficient capital to fund operations into the third quarter of 2028.10-Q, Nov 2026
Raised after last reported balance sheet (Oct 2026) -10
Share count 111,660,283 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full RCKT picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RCKT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.